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Case report
solitary breast metastasis from oestrogen reCeptor-
positive pulmonary adenoCarCinoma: report of a Case 
with a potential pitfall
Gábor Cserni
University of Szeged, Hungary
Solitary breast metastases are rare and mimic primary breast carcinoma. A 60-year-
old female with a history of pulmonary adenocarcinoma presented with a solitary 
left breast lump suspicious for malignancy on breast imaging. Core-needle biopsy 
disclosed an adenocarcinoma strongly and diffusely positive for oestrogen recep-
tors. Further immunohistochemistry was consistent with the breast tumour being 
a solitary metastasis of her pulmonary cancer. Clinicians and pathologists should be 
aware of the fact that pulmonary adenocarcinomas may sometimes display strong 
rather than only focal positivity for oestrogen receptors by immunohistochemistry 
and may mimic breast cancer of no special type.
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Introduction
According to the Cancer Facts and Figures pub-
lication of the American Cancer Society, the lifetime 
risk of males and females for developing a malignant 
tumour is between 1 out of 2 or 3 [1]. Therefore, the 
risks of having multiple primary tumours in a patient 
are relatively high. The treatment strategies for stage 
IV metastatic carcinomas and multiple early stage 
primary cancers are obviously different. A metasta-
sis to an organ, like the breast, where most malig-
nant tumours are primary cancers, may give rise to 
misdiagnosis as a primary neoplasm, especially if the 
metastatic lesion shares features with the morpholo-
gy of primary carcinomas. We report a case in which 
oestrogen receptor positivity of the breast metastasis, 
a common feature of primary breast carcinomas, pre-
disposed for a potential misdiagnosis.
Case report
A 60-year-old cachectic female presented at 
the Breast Imaging Unit of Bács-Kiskun County 
Teaching Hospital in June 2015 for the evaluation 
of a lump observed two months earlier. A circum-
scribed, palpable, and mobile mass of 8 mm in great-
est dimension was identified in the axillary tail of her 
left breast (Fig. 1A). Mammography and ultrasound 
findings were suspicious for malignancy, scored as BI-
RADS 4C, and a core-needle biopsy was performed. 
All tissues described were fixed in neutral buffered 
formalin, and were embedded in paraffin. The bi-
opsy showed a gland forming adenocarcinoma with 
desmoplastic reaction and no specific features, simu-
lating breast cancer of no special type (ductal carci-
noma) [2], morphologically the most heterogeneous 
group among breast cancers (Fig. 1B).  No associated 
ductal carcinoma in situ was present. The tumour 
could have been graded as well-differentiated, Grade 
I according to the Nottingham grading scheme [3], 
with scores of tubule formation – 1; nuclear pleomor-
phism – 3; and high power field area adjusted mitotic 
count – 1. Routine assessment of oestrogen receptors 
(ER) and progesterone receptors (PR) as well as hu-
man epidermal growth factor receptor-2 (HER2) was 
done using conventional immunohistochemistry. The 
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Fig. 1. Morphology of the breast lesion and the primary lung adenocarcinoma. A) Magnification mammographic view 
of the lesion (arrow) in the axillary tail of the left breast. B) Gland forming adenocarcinoma without features of special 
types of breast cancer in the core-needle biopsy specimen (haematoxylin and eosin, magnification 10×). C) Strong and 
diffuse positivity for oestrogen receptor with the SP1 antibody (magnification 10×). D) Gross view of the relatively cir-
cumscribed tumour (arrow) after its removal. E) Diffuse Napsin-A staining of the breast tumour (magnification 20×). 
F) Focal oestrogen receptor positivity of the pulmonary adenocarcinoma with the SP1 antibody (magnification 40×)
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antibodies used are listed in Table I. The tumour was 
found to be strongly and diffusely (about 95% of the 
cells) positive for ER-α using the 6F11 antibody, re-
sulting in an Allred score of 8 [4], and was negative 
for PR (with one or two cells, and obviously < 1% 
of the cells staining weakly) and HER2 (no staining 
at all) [5, 6]. Because the anamnestic data mentioned 
a lung adenocarcinoma diagnosed previously, a TTF-1 
immunostain was also done and resulted in posi-
tive staining of many nuclei. The ER staining was 
repeated with an alternative antibody (SP1) and 
resulted in a similarly strong and diffuse staining 
(Fig. 1C). Napsin-A was diffusely and strongly pos-
itive with a characteristic granular cytoplasmic pat-
tern (Fig. 1E), whereas GATA-3 and mammaglobin 
were negative in the tumour. The bronchial biopsy 
of the lung adenocarcinoma could not be further 
assessed because it was used for diagnostic and mo-
lecular testing, without remnants. The original im-
munostains obtained (p63–, CK7+, TTF1+) had 
the same staining profile in the breast needle biopsy 
specimen. The tumour was diagnosed as a solitary 
metastasis of a pulmonary adenocarcinoma being 
unusually strongly and diffusely positive for ER-α. 
The tumour was excised (Fig. 1D), but the patient 
refused any further treatment (ALK-EML4 translo-
cation was later tested from this specimen with a Vy-
sis FISH break-apart probe [Abbott Molecular, Des 
Plaines, Illinois, USA] and was absent from the tu-
mour cells). Multidisciplinary discussion of the case 
revealed that the patient had a right upper lobec-
tomy for pulmonary adenocarcinoma in September 
2003. This was diagnosed as a “bronchioloalveolar 
carcinoma” at that time. The patient had declined 
adjuvant systemic treatment. The tumour recurred 
locally in December 2013 (the mass around the right 
main bronchus extending to the distal trachea was 
interpreted as recurrence), when a course of pallia-
tive systemic treatment (four cycles of bevacizumab, 
paclitaxel, and carboplatinum followed by three of 
erlotinib) was administered (the biopsy was classi-
fied as having a dual wild type after testing for exon 
18-21 activating mutations of the epidermal growth 
factor receptor and mutations in codons 12-13 of 
K- and N-RAS). The mammography performed as 
a follow-up of a contralateral microcalcification in 
August and the positron emission tomography/com-
puted tomography performed in November 2014 did 
not show the breast lesion, and the patient had no 
other distant metastasis detected at the time of the 
diagnostic work-up of the breast lump. The archived 
lobectomy specimen was retrospectively tested for 
ER and PR: the lepidic adenocarcinoma displayed ER 
positivity (about 50% of the cells with a medium av-
erage staining intensity – Allred score 6 with the SP1 
antibody and weaker, Allred score 4, with the 6F11 
antibody) (Fig. 1F) and was also focally positive for 
PR (about 5% of cells staining, Allred score 4). This 
proved that the primary tumour was already positive 
for these steroid hormone receptors.
The metastasis was a proof of progression, and the 
patient – after a voluntary drug holiday of six months 
– received further palliative systemic treatment (per-
metrexed 12 times). In March 2017, she is alive and 
receiving vinorelbine as fourth-line treatment in her 
palliative care. The patient gave written consent for 
the publication of her case. 
Discussion
To the author’s knowledge, this is the first report 
of a solitary metastasis from an ER-positive pulmo-
Table I. Antibodies used for the immunohistochemistry
antibody Clone sourCe dilution result
ER 6F11 Novocastra (Leica), Newcastle, UK 1 : 40 Diffusely positive
ER SP1 Ventana Medical Systems, Tucson, AZ RTU Diffusely positive
CK7 OV-TL 12/30 Biogenex, Fremont, CA 1 : 200 Diffusely positive
GATA-3 HG3-31 Santa Cruz Biotechnology, Santa Cruz, CA 1 : 50 Negative
GCDFP-15 23A3 Cell Marque, Rocklin, CA 1 : 200 Negative
MGB 1A5 Biocare Medical, Concord, CA RTU Negative
Napsin-A Polyclonal 
(352A-74)
Cell Marque, Rocklin, CA 1 : 400 Diffusely positive
p63 4A4 Histopathology Kft, Pécs, Hungary 1 : 400 Negative
PR PGR312 Novocastra (Leica), Newcastle, UK 1 : 200 Negative (<1% weak)
TTF-1 8G7G3/1 Biocare Medical, Concord, CA 1 : 200 Focally positive
ER – oestrogen receptor; CK7 – cytokeratin 7; GATA-3 – GATA binding protein 3; GCDFP-15 – gross cystic disease fluid protein 15; MGB – mammaglobin;  
PR – progesterone receptor; TTF-1 – thyroid transcription factor 1; RTU – ready-to-use
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nary adenocarcinoma to the breast. The recognition 
of the tumour as a metastatic one partially relied on 
the knowledge of a coexisting recurrent pulmonary 
adenocarcinoma, which stimulated the routine prog-
nostic and predictive immunohistochemistry (ER, 
PR, HER2) panel performed on diagnostic breast 
core-needle biopsies to be complemented with mark-
ers of pulmonary origin (TTF1, Napsin-A). The 
proper identification of the metastasis as a secondary 
tumour allowed the omission of systemic treatment 
used for breast cancers and resulted in a change in the 
systemic palliative therapy of the lung tumour. The 
patient has a survival characteristic of oligometastat-
ic disease, which is better than that of patients with 
advanced metastases [7]. 
The majority of breast cancers are ER-positive, 
and ER expression is often considered as evidence in 
favour of mammary origin. Most recently ER-positiv-
ity of lung adenocarcinomas has been reported with 
a range of 0 to 97% [8, 9]. Positivity is seen especially 
with SP1 (and with decreasing frequently with 6F11 
or 1D5, the latter of which was first reported not to 
stain lung adenocarcinomas at all [10]); the staining 
is generally only focal, and has been more common in 
non-mucinous lepidic adenocarcinomas [8]. Accord-
ing to the described findings, the present tumour 
could be confidently diagnosed as of pulmonary or-
igin. There were features against a primary breast 
cancer: no in situ carcinoma was present around the 
invasive tumour, which was relatively circumscribed 
like most metastases, but not unlike some breast pri-
maries; except for ER, no markers of primary breast 
origin (GCDFP-15, mammaglobin, GATA-3) were 
positive in the tumour. In contrast, markers of pul-
monary origin (TTF-1 and Napsin-A) were positive. 
Neither of these markers are 100% specific and/or 
sensitive, but the overall pattern is in keeping with 
a pulmonary origin [11, 12]. Metastases to the breast 
are rare, and pulmonary adenocarcinomas are un-
common sources of such seeding [13]. Of 12 pulmo-
nary adenocarcinomas metastatic to the breast iden-
tified through a PubMed search spanning 20 years, 
only five were tested for ER, and none were positive 
[13]. However, an antibody-dependent focal ER pos-
itivity should be expected in at least some, if not the 
majority, of pulmonary adenocarcinomas according 
to the literature [8, 9, 10], and the reported case sug-
gests that even strong and diffuse positivity may oc-
cur. This would add pulmonary adenocarcinomas to 
cancers of the breast and genital tract (ovarian, tubal, 
endometrial carcinomas) on the list of tumours ex-
pressing ER to be considered as potential sources of 
ER-positive metastatic tumours.  
Pathologists as well as clinicians should be aware 
of this presentation, and should remember that some 
lung adenocarcinomas may strongly and diffusely 
rather than only focally be positive for ER-α with 
the 6F11 and SP1 monoclonal antibodies used in this 
case. To our knowledge this is the first description of 
a solitary ER-positive breast metastasis from a pul-
monary adenocarcinoma.
Conclusions
The reported case highlights that ER positivity may 
be prominent in some primary or metastatic lung ad-
enocarcinomas. It is recommended to test ER-positive 
tumours lacking obvious signs of a primary nature, 
like the one presented here with markers of pulmo-
nary origin, because this may help in avoiding poten-
tial diagnostic pitfalls (such as a primary breast cancer 
in analogy to the present case, or metastatic ER-posi-
tive breast or gynaecological cancer in the lung as an 
extrapolation from this case) and in treating the pa-
tients according to the correct diagnosis.
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